LC
CUE icon

Lindbrook Capital’s Cue Biopharma CUE Stock Holding History

Lindbrook Capital’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-667
Closed -$98K – 2531
2022
Q1 		$98K Hold
667
– – 0.02% 473
2021
Q4 		$226K Hold
667
– – 0.03% 279
2021
Q3 		$291K Hold
667
– – 0.08% 109
2021
Q2 		$233K Hold
667
– – 0.05% 145
2021
Q1 		$244K Hold
667
– – 0.05% 136
2020
Q4 		$250K Hold
667
– – 0.06% 122
2020
Q3 		$301K Buy
+667
New +$384K 0.08% 97

Other funds holding CUE

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Lindbrook Capital's CUE Position: Q2 2022 in Review

Lindbrook Capital sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 667 shares — an estimated $98K sold.

Lindbrook Capital first reported a position in CUE in Q3 2020 and held it in 7 quarters. The position peaked at $301K in Q3 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

  • Lindbrook Capital reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
  • Lindbrook Capital sold 667 Cue Biopharma shares in Q2 2022, an estimated $98K.
  • Lindbrook Capital first reported a position in Cue Biopharma in Q3 2020 and held it in 7 quarters.
  • Lindbrook Capital's Cue Biopharma position peaked at $301K in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on Lindbrook Capital's 13F filing for Q2 2022, filed 1 Aug 2022.